Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DFLR heading back up, CNES only has a few bids under .003
CardioGenesis Announces FDA Approval of Advanced TMR Laser
New SolarGen 2100s - First of a Series of Products to Expand TMR Market
FOOTHILL RANCH, Calif., Dec. 28 /PRNewswire-FirstCall/ -- CardioGenesis
Corporation (OTC Bulletin Board: CGCP), the market leader in surgical products
and accessories used in angina-relieving Transmyocardial Revascularization
(TMR) and Percutaneous Myocardial Channeling (PMC) procedures, today announced
the FDA approval of the SolarGen 2100s, an advanced laser console for
performing TMR.
Chairman and CEO, Michael J. Quinn explained that "the SolarGen 2100s is
the first in a series of significant, advanced product offerings intended to
expand the TMR market. In the past 12 months, working closely with leading
cardiovascular practitioners, we have implemented a minimally invasive
initiative that will dramatically change the way TMR is performed, and how it
is viewed by patients and referring physicians. Our minimally invasive
strategy is consistent with the overriding trend in cardiovascular care ...
providing improved patient outcomes with reduced morbidity and risk."
The Company has been preparing for the launch of the advanced TMR
products, which they are naming the TMR PLUS(TM) platform. This advanced
SolarGen 2100s is an important component of the new and improved TMR platform,
as it removes many of the obstacles to performing the procedure that are
directly related to the existing TMR technology.
"The SolarGen 2100s represents a significant platform advancement in the
application of TMR in the operating room," Mr. Quinn stated. "The
substantially reduced size and footprint of the SolarGen console, the
flexibility of the power requirements, and the instantaneous system start up -
- are all important benefits of this advanced technology. It dramatically
increases the advantages of our platform to the hospital and the practitioner
in terms of clinical ease of use."
The TMR PLUS platform will include a full range of minimally invasive
delivery systems designed to reduce the morbidity associated with standard
open surgical techniques, while adding technological features to enhance the
physician's ability to visualize and treat all targeted areas of the left
ventricle. Mr. Quinn stated, "FDA approval of the SolarGen 2100s is an
important step forward for our Company. We are excited to launch this first
component of our advanced TMR PLUS platform, which we expect to be followed
shortly by the approval of the first of our minimally invasive delivery
systems. We expect this advanced TMR console to help increase the utilization
rates at TMR centers around the country, and provides us with the opportunity
to significantly grow capital revenue for the first time since the initial
approval of TMR."
Quinn emphasized that in 2005 the company is asserting itself as an
innovative cardiovascular company providing tools for improved patient
outcomes. The Company is preparing for the launch of its advanced TMR PLUS
platform, as well as the CelleratOR system for point of care preparation of
platelet rich plasma. He added, "We will continue to add to our market basket
of innovative products, focusing on devices and therapies designed to treat
advanced cardiovascular disease. 2005 is our opportunity to achieve
significant revenue growth from these new products, and those we expect to add
in the near future." Additionally, the Company recently launched a direct to
physician and direct to patient web site (www.heartofnewlife.com) regarding
TMR to help accelerate the awareness of TMR.
The company intends to highlight the advanced SolarGen 2100s TMR console,
along with its minimally invasive TMR delivery systems that are currently in
the regulatory process, and the CelleratOR system for point of care
preparation of autologous platelet rich plasma at an educational symposium in
conjunction with the STS meeting in January.
About CardioGenesis Corporation
CardioGenesis is a medical device company specializing in the treatment of
cardiovascular disease and is a leader in devices that stimulate cardiac
angiogenesis. The Company's market leading Holmium: YAG laser system and
disposable fiber-optic accessories are used to perform a FDA-cleared surgical
procedure known as Transmyocardial Revascularization (TMR) to treat patients
suffering from angina. Surgical products and accessories for the
CardioGenesis TMR procedure, which are marketed in the U.S. and around the
world, have been shown to reduce angina and improve the quality of life in
patients with coronary artery disease. Surgical products and accessories for
the Company's minimally invasive Percutaneous Myocardial Channeling (PMC)
procedure are currently being marketed in Europe and other international
markets.
For more information on the Company and its products, please visit the
CardioGenesis company web site at www.cardiogenesis.com. or the patient and
physician website at www.heartofnewlife.com. heartofnewlife.com is a resource
for patients and physicians which provides medical information on TMR
With the exception of historical information, the statements set forth
above include forward-looking statements. Any forward-looking statements in
this news release related to the Company's sales, profitability, the adoption
of its technology and products and FDA clearances are based on current
expectations and beliefs and are subject to numerous risks and uncertainties,
many of which are outside the Company's control, that could cause actual
results to differ materially. Factors that could affect the accuracy of these
forward-looking statements include, but are not limited to: any inability by
the Company to sustain profitable operations or obtain additional financing on
favorable terms if and when needed; any failure to obtain required regulatory
approvals; failure of the medical community to expand its acceptance of TMR or
PMC procedures; possible adverse governmental rulings or regulations,
including any FDA regulations or rulings; the Company's ability to comply with
international and domestic regulatory requirements; possible adverse Medicare
or other third-party reimbursement policies or adverse changes in those
policies; any inability by the Company to ship product on a timely basis; the
Company's ability to manage its growth; adverse economic developments that
could adversely affect the market for our products or our ability to raise
needed financing; actions by our competitors; and the Company's ability to
protect its intellectual property. Other factors that could cause
CardioGenesis' actual results to differ materially are discussed in the "Risk
Factors" section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2003, the Company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2004, and the Company's other recent SEC filings.
The Company disclaims any obligation to update any forward-looking statements
as a result of developments occurring after the date of this press release.
For further information, please contact: Michael J. Quinn, Chairman and
CEO, +1-714-649-5050, or Richard Lanigan, Senior VP, Marketing,
+1-714-649-5024, both of CardioGenesis Corporation.
SOURCE CardioGenesis Corporation
-0- 12/28/2004
/CONTACT: Michael J. Quinn, Chairman and CEO, +1-714-649-5050, or Richard
Lanigan, Senior VP, Marketing, +1-714-649-5024, both of CardioGenesis
Corporation/
/Web site: http://www.heartofnewlife.com /
/Web site: http://www.cardiogenesis.com /
(CGCP)
CO: CardioGenesis Corporation
ST: California
IN: HEA MTC BIO OTC
SU: PDT
Xmas must have been expensive!!!
I guess everybody wants to make some $$$
Absolutely. There are only about 3 people on the boards who do what you do.
Hope you had a good Xmas. Good luck for 2005.
Ronnie - did all your free week trails run out???
ICAN Jan 7, you get a divy of 10 free trading shares for every 100 shares you own on that date, I have been watching this one for a while and it seems like the floor is 0.0003 not a bad deal IMO!
BLFE. Great rebound play. DD it as IR man said large seller has moved off, and PR's should be out in the New Year.
http://stockcharts.com/def/servlet/SC.web?c=blfe,uu[w,a]daclyiay[dd][pb32!h.02,.20!f][vc60][iut!Ug!U....
Ronnie looks like your pal EVO's board has gone premium. You could suck in all the freebies here.
Watch CESY. It will continue to run. After Christmas, skyrocket time. Possibly over 5 cents, just look at the JEFF ask.
GLVP a winner today, so is NMCX (which I called on Monday)
SPRU new ticker SPRL multi bagger green ....more to come OIL
OIL YAHOOOO !
doing good oil, how about you?? your missing great plays here :)
gone most of the day, RONNIE! how ya do?
Keith
PABN is running through the roof!!!
nsol 2004-12-21 14:00:19
Nuclear Solutions Technology Update: Application Feasibility of Gravity Based Detection for Shielded Nuclear Weapons validated by U.S. Government Sponsored Research
>
WASHINGTON, Dec. 21, 2004 (PRIMEZONE) -- Nuclear Solutions, Inc. (OTCBB:NSOL)
released the following:
Use of gravity to detect nuclear weapons was researched by the U.S. government
in the early 1990s and found to be potentially viable for arms control
applications under the Strategic Arms Reduction Treaty (START). Now Nuclear
Solutions, Inc. is working to produce a gravimetric sensor that overcomes the
limitations of previous designs for the purpose of practically and effectively
detecting a "loose nuke" in transit through a border entry point.
"The levels of radiation emitted by weapons-grade plutonium and uranium are
relatively low, and easy to shield," said Nuclear Solutions Chief Executive
Officer Patrick Herda, "which makes conventional detection practically
impossible under several very likely transit scenarios."
The Defense Nuclear Agency (DNA) has previously sponsored research and
experimentation into the concept of detecting and quantifying nuclear warheads
for arms control verification applications by measuring their associated
gravitational signatures. Proof-of-principle experiments were performed to
characterize the capabilities and limitations of gravimetric detection for
applications related to START.
The research report, entitled Proof of Principle Tests: Gravity Gradiometer
Utility for Onsite Inspection Applications (Contract No. DNA001-90-C-0168),
concluded, "Using current gravity gradiometer technology, (it was) demonstrated
that gravitational signatures of simulated (weapons) can be measured
successfully" and that "gravity gradiometry accurately and reliably
discriminated small variations in mass distributions as well as small
asymmetries in mass."
Although the experiment validated the potential utility of using gravitational
signatures for arms control applications, it did not address the problems
anticipated in gravitational signature collection in an actual inspection. It
found that "identification of a particular missile system (i.e., its specific
identity) will require future signal analysis and algorithm development."
"I found the experimental results from the DNA report to be very encouraging for
our present development effort," Herda said, "keeping in mind that the previous
experiment did not evaluate our new approach and should not be mistaken for
government validation of our patent-pending technology."
He added, however, "the principle of measuring changes in gravitational fields
to determine the existence of a mass anomaly that could signal the presence of
heavy metals was successfully carried out in the DNA experiment, and its
feasibility, given a robust and fieldable sensor pack, is not in question."
Development of Nuclear Solutions' new sensing concept may result in a highly
sensitive, portable, and low-cost detection system that responds to minute
gravitational gradient anomalies produced by high-density nuclear materials like
plutonium and uranium -- and is unaffected by radiation shielding techniques.
When fully funded and developed, this patent-pending approach using gravimetric
sensing techniques could become a useful tool in the fight against nuclear
terrorism worldwide.
Nuclear Solutions is progressing as anticipated with its intellectual property
development, and further updates concerning the company's shielded nuclear
weapons detection technology and European business development activities are
expected within the next two weeks. Additionally, a progress update on nuclear
micro-battery technology is expected by the end of January.
About Nuclear Solutions, Inc.:
Nuclear Solutions, based in Washington, D.C., is an emerging innovative
technology development company that is committed to exploring, developing, and
commercializing viable product technologies enabling partner companies to offer
new and improved products in the following areas:
Nuclear Weapon Detection for Homeland Security & Defense
The development of advanced technology to detect shielded nuclear materials and
terrorist nuclear weapons
Nanotechnology/MEMS applications
The development of long-lived nuclear micro-power sources, based on three U.S.
Patents (5,087,533; 6,118,204; 6,238,812), to power applications in the emerging
field of Nanotechnology, Micro-Electro-Mechanical Systems, and the new
generation of low power microelectronics.
Environmental Technology
Development of a patent pending process to remediate tritiated water via an
advanced separation technique.
More information about Nuclear Solutions, Inc. may be found on its website,
www.nuclearsolutions.com.
Disclaimer: The matters discussed in this press release are forward-looking
statements that involve a number of risks and uncertainties such as our plans,
objective, expectations and intentions. You can identify these statements by our
use of words such as "may," "when," "expect," "believe," "anticipate," "intend,"
"could," "estimate," "goal," "continue," "plans," "planning," "would," "when,"
"feasible," or other similar words or phrases. Some of these statements include
discussions regarding our future business strategy and our ability to generate
revenue, income, and cash flow. Additional funding is required to develop the
technology described herein. The actual future results for the Company could
differ significantly from those statements. Factors that could adversely affect
actual results and performance include, among others, the Company's limited
operating history, dependence on key management, financing requirements,
technical difficulties commercializing any projects, government regulation,
technological change, and competition. In any event, undue reliance should not
be placed on any forward-looking statements, which apply only as of the date of
this press release. Additionally, patent pending status does not guarantee that
a patent will issue or that the technologies herein, including gravimetric
sensor technology will be commercially successful. Accordingly, reference should
be made to the Company's periodic filings with the U.S. Securities and Exchange
Commission.
CONTACT: John Dempsey, Vice-President
Nuclear Solutions, Inc.
202-787-1951
info@nuclearsolutions.com
SGLI poised to move within a few days imho
$$$$$$ronnies runners$$$$$$
ALL Exchnages including Stocks in the ranges .0001- over $100,000.00 including ,u decide when to buy.
.
Feel free to post your own picks here.
Feel free to speak your mind.
Feel free to make money w/me.
quick links
http://www.pinksheets.com
http://www.otcbb.com
http://www.stockcharts.com
Subscribe to Investorshub
http://www.investorshub.com/boards/subscribe.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |